{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-212597","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.880814+00:00","generated_at":"2026-06-24T04:20:13.154866+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio Q2 2022 revenue $73.7M, net loss $9.9M; cash $688.6M; pipeline data positive","bullets":["Net loss attributable to common stockholders of $9.9M ($0.07 per share) vs $96.3M loss a year ago; revenue $73.7M from NULIBRY and licensing.","Cash and equivalents $688.6M, providing runway into 2024; two-year deferral on senior debt principal repayment to Nov 2026.","Positive Phase 2 interim data for infigratinib in achondroplasia: mean AHV increase 1.52 cm/year; added Cohort 5.","Entered exclusive license with BMS for BBP-398 (SHP2 inhibitor) for up to $905M; received $90M upfront; sold PRV for $110M.","Selected next-gen KRAS G12C dual inhibitor candidate; plans to begin clinical work mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-212597","json":"https://secwatch.observer/filing/0001193125-22-212597.json","markdown":"https://secwatch.observer/filing/0001193125-22-212597.md","text":"https://secwatch.observer/filing/0001193125-22-212597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000119312522212597/0001193125-22-212597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000119312522212597/d365371d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:20:13.154866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}